
Pharvaris B.V. (PHVS) Stock Forecast & Price Target
Pharvaris B.V. (PHVS) Analyst Ratings
Bulls say
Pharvaris NV has significantly increased its global peak sales estimate for deucrictibant to $1.65 billion by 2037, reflecting rising confidence in the drug's market potential. Positive clinical data indicates that 100% of participants in key studies achieved "well-controlled HAE" status and reported improvements in health-related quality of life, suggesting strong therapeutic effectiveness. The estimated prevalence of HAE, combined with the lack of approved therapies, positions deucrictibant favorably for gaining substantial market share if approved, enhancing the company's outlook in the biopharmaceutical sector.
Bears say
Pharvaris NV faces a negative outlook primarily due to the insufficient de-risking of bradykinin B2 receptor antagonism in the chronic prophylaxis setting, which raises questions about the therapeutic effectiveness of their lead candidate. Additionally, the highly competitive market for hereditary angioedema treatment is dominated by established therapies, posing significant challenges for market entry and acceptance of deucrictibant. Compounding these issues, the emergence of multiple subcutaneous therapies set to receive approval within the next three years could further exacerbate the risk of market share erosion for Pharvaris.
This aggregate rating is based on analysts' research of Pharvaris B.V. and is not a guaranteed prediction by Public.com or investment advice.
Pharvaris B.V. (PHVS) Analyst Forecast & Price Prediction
Start investing in Pharvaris B.V. (PHVS)
Order type
Buy in
Order amount
Est. shares
0 shares